The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

EU-wide position versus national implementation — what changed since

This is a generated summary. It shows the 5 most-liked posts from a topic of 27, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
VD
vial_deskTL3Regular11 Nov 2025#7

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

20 likes 8mo
TW
t.waldenstrmTL2Member24 Dec 2025#11

post #10 is right about the mechanism and I think understates the practical bit.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

27 likes 7mo
B
BuchholzTL2Member20 Feb 2026#17
Nicolaides, post #1: EU-wide position versus national implementation — what changed since Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what determines the answer. Denial received, with a stated reason. My reading of the reason is that it tells me… Go to post

France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.

26 likes in reply to #1 5mo
KC
k.chukwuTL2 Moderator19 Mar 2026#20
j.solberg, post #14: Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available. Go to post

Italy: AIFA controls reimbursement through a note system. Weight-management indications have not attracted public reimbursement. Regional health authorities add further variation.

28 likes in reply to #14 4mo
EM
e.mikkelsenTL2Member22 Apr 2026#24

Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters.

23 likes 3mo

Read the full topic (27 posts)

Promoted into the documentation commons. The content of this topic is maintained at Access notes: Italy, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

Suggested topics

TopicParticipantsRepliesViewsActivity
Cross-border purchase rules within the EU
On the subject in the title: Cross-border purchase rules within the EU Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what determines the answer.…
HMEFVKGZA+45 49 15k 8mo
Revisiting: German, French and Dutch differences, compared
Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. A coverage question with the paperwork detail included, since…
ITKSTHEDS+90 99 32k 9mo
Reimbursement variation across member states
Reimbursement variation across member states Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
SFJSREBS+7 11 39k 3mo
Coming back to: Cross-border purchase rules within the EU
Cross-border purchase rules within the EU Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
JEDBNRPFFE+12 16 2.8k 11mo
EU-wide position versus national implementation
EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category…
BBCLSGLEVK+22 29 356 11mo

Related topics — sharing the tags EMA, cost per milligram, personal import

TopicParticipantsRepliesViewsActivity
Managing an unplanned gap in supply
Managing an unplanned gap in supply — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the answer.…
LSFPASLCVK+105 110 5.1k 3mo
Second pass at: Import rules for personal quantities, by jurisdiction, dated
Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are…
DHKAV 2 5k 11mo
Research-use-only labelling: what it means and what it does not — the long version
Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not — the long version Everything below is what sits behind that. I would like to talk about…
GLSHKKK+150 158 55k 14mo
Cost per milligram, computed honestly across formats
Posting this under the heading it deserves: Cost per milligram, computed honestly across formats Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
BVTDV 2 47k 18mo
What a regulator's shortage notice actually authorises
What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked. A logistics question, since the answers here are usually better…
BESCAAQLSG+8 12 15k 17h